Latest Tax Incentives News

The Arkansas Oil & Gas Commission has approved a 2.5% lithium royalty for brine projects, providing Pantera Lithium with regulatory clarity and a competitive fiscal framework that enhances its Smackover Project’s commercial prospects.

Careteq Limited faces a significant repayment demand from the ATO over R&D tax claims but is mounting a formal objection backed by legal counsel.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

Ardea Resources has received a $1.2 million R&D tax incentive rebate from the Australian Government, reinforcing its innovative work at the Kalgoorlie Nickel Project and strengthening its financial position.

MTM Critical Metals has locked in a pre-permitted industrial site in Texas, positioning itself to commission its innovative metal recovery plant by year-end 2025 and accelerate U.S. commercial expansion.

Papyrus Australia has issued a revised Appendix 4C for the March 2025 quarter, correcting the treatment of $527k in R&D expenditure previously reported as cash payments. This adjustment also impacts prior monthly and quarterly cash flow reports dating back to November 2024.

Elixir Energy has successfully closed its Share Purchase Plan, raising an additional $117,000 and bringing total capital raised to $7.1 million, supported by new shares and free attaching options.

Assetora Limited has dramatically reduced its net liabilities and strengthened its balance sheet through strategic capital raises and debt conversions, while unveiling a comprehensive rebrand and leadership expansion to drive its next growth phase.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy by executing three CAR-T term sheets and completing technical due diligence, while implementing cost-cutting measures and seeking new capital amid a tough financing environment.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.